Business Corpus: IBD 50's Supernus Pharma Tops Quarterly ExpectationsSupernus Pharmaceuticals on Wednesday reported income of 57 cents per share on sales of $99.5 million for its second quarter. The post IBD 50's Supernus Pharma Tops Quarterly Expectations appeared first on Investor's Business Daily.

[Collection]

Supernus Pharmaceuticals (SUPN) on Wednesday reported income of 57 cents per share on sales of $99.5 million for its second quarter. In the year-earlier period, it reported earnings of 32 cents per share on $75.8 million in sales.

Analysts polled by Zacks Investment Research had called for profit of 44 cents per share on $101 million in sales.

For the year, Supernus guided to $385 million to $400 million in net product sales. The consensus had modeled earnings of $1.86 per share and $405 million in sales.

In premarket trading on the stock market today, Supernus stock wasn't yet active. Supernus is on the IBD 50 and is also a Sector Leader. It has a Composite Rating of 98 out of a best-possible 99, trailing only Ligand Pharmaceuticals (LGND) in the biotech group.